Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such
as rituximab, can block cancer cell growth in different ways. Some block the ability of
cancer cells to grow and spread. Others find cancer cells and help kill them or carry
cancer-killing substances to them. Giving bortezomib together with rituximab may kill more
cancer cells.
PURPOSE: This phase II trial is studying how well giving bortezomib together with rituximab
works in treating patients with post-transplant lymphoproliferative disorders.